As such, enhanced expression and exaggerated activation of GPCRs and G proteins (e.g., CXCR4 and Gγ9) may represent crucial mechanisms responsible for the enhanced activation of the oncogenic ERK1/2 pathway in prostate cancer. This evidence concerns the gene MAPK3 and prostate carcinoma.